EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction

Erica Acquarone, Elentina K Argyrousi, Ottavio Arancio, D Martin Watterson, Saktimayee M Roy

Journal of Alzheimer's Disease · 2024

DOI: 10.3233/jad-240063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Erica Acquarone und 4 weiteren Autor:innen. Beteiligte Einrichtung: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Background: Neurodegenerative diseases manifest behavioral dysfunction with disease progression. Intervention with neuropsychiatric drugs is part of most multi-drug treatment paradigms. However, only a fraction of patients responds to the treatments and those responding must deal with drug-drug interactions and tolerance issues generally attributed to off-target activities. Recent efforts have focused on the identification of underexplored targets and exploration of improved outcomes by treatment with selective molecular probes.

Objective

As part of ongoing efforts to identify and validate additional targets amenable to therapeutic intervention, we examined levels of the serotonin 5-HT2b receptor (5-HT2bR) in Alzheimer’s disease (AD) brains and the potential of a selective 5-HT2bR antagonist to counteract synaptic plasticity and memory damage induced by AD-related proteins, amyloid-β, and tau.

Methods

This work used a combination of biochemical, chemical biology, electrophysiological, and behavioral techniques. Biochemical methods included analysis of protein levels. Chemical biology methods included the use of an in vivo molecular probe MW071, a selective antagonist for the 5HT2bR. Electrophysiological methods included assessment of long-term potentiation (LTP), a type of synaptic plasticity thought to underlie memory formation. Behavioral studies investigated spatial memory and associative memory.

Results

5HT2bR levels are increased in brain specimens of AD patients compared to controls. 5HT2bR antagonist treatment rescued amyloid-β and tau oligomer-induced impairment of synaptic plasticity and memory.

Conclusions

The increased levels of 5HT-2bR in AD patient brains and the attenuation of disease-related synaptic and behavioral dysfunctions by MW071 treatment suggest that the 5HT-2bR is a molecular target worth pursuing as a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAnimalsHumansAmyloid beta-PeptidesBrainDisease Models, AnimalHippocampusLong-Term PotentiationMemory DisordersSpatial MemoryReceptor, Serotonin, 5-HT2B

Stichwörter der Autor:innen

5HT2b receptorAlzheimer’s diseaseantagonistlong-term potentiationmemory

Substanzen

Amyloid beta-PeptidesHTR2B protein, humanReceptor, Serotonin, 5-HT2B

Autor:innen und Institutionen

  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA.
  • Department of Internal Medicine, Columbia University, New York, NY, USA.
  • Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
  • Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Acquarone, E., Argyrousi, E. K., Arancio, O., Watterson, D. M., & Roy, S. M. (2024). The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-240063

Vancouver

Acquarone E, Argyrousi EK, Arancio O, Watterson DM, Roy SM. The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-240063

BibTeX
@article{Acquarone2024,
  author = {Acquarone, Erica and Argyrousi, Elentina K and Arancio, Ottavio and Watterson, D Martin and Roy, Saktimayee M},
  title = {The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction},
  journal = {Journal of Alzheimer's Disease},
  year = {2024},
  doi = {10.3233/jad-240063}
}
Kostenlos starten →